Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Results Conference Call May 5, 2023 8:00 AM ET

Company Participants

Cristi Barnett - Corporate Communications and IR

Gilmore O’Neill - CEO

Baisong Mei - Chief Medical Officer

Michelle Robertson - CFO

Conference Call Participants

Joon Lee - Truist Securities

Samantha Semenkow - Citi

Dae Gon Ha - Stifel

Steve Seedhouse - Raymond James

Yanan Zhu - Wells Fargo

Ernie Rodriguez - Cowen

Rick Bienkowski - Cantor Fitzgerald

Rich Law - Credit Suisse

Ry Forseth - Guggenheim

Luca Issi - RBC Capital Markets

Cheng Li - Oppenheimer

Operator

Good morning, and welcome to Editas Medicine’s First Quarter Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the Company’s request.

I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine.

Cristi Barnett

Thank you, Camilla. Good morning, everyone, and welcome to our first quarter 2023 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today’s call will be available in the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC as updated by our subsequent filings.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change.

Now, I will turn the call over to our CEO, Gilmore O’Neill.

Gilmore O’Neill

Thank you, Cristi, and good morning, everyone. Thank you for joining us today on Editas’ first quarter earnings call. I’m joined today by two other members of the Editas executive team, Baisong Mei, our Chief Medical Officer; and Michelle Robertson, our Chief Financial Officer.